Home > News > Interview with Karen J. Brunke, Ph. D. at Targesome, Inc.
January 20th, 2003
Interview with Karen J. Brunke, Ph. D. at Targesome, Inc.
Targesome Inc., co-founded by Drs. King Li and Mark Bednarski in late 1999, is developing nanoparticles that can be used for drug delivery. Any drug can be attached to the surface of the nanoparticle, resulting in improved therapeutic properties such as efficacy, safety, and increased half-life in the blood for small molecule drugs (thereby allowing less frequent intravenous dosing).
Arrowhead Expands Management Team with Appointment of Susan Boynton as Vice President Global Regulatory Affairs October 1st, 2014
Nanobotmodels present metastasis and angiogenesis medical animation October 1st, 2014
'Stealth' nanoparticles could improve cancer vaccines October 1st, 2014
New Absorber Will Lead to Better Biosensor: Biosensors are more sensitive and able to detect smaller changes in the environment October 1st, 2014